Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

GSK touts Anoro results as it preps for generic attacks on $8B-seller Advair

14.03.2014 / Fierce Pharma

With aging top dog Advair losing ground to generic and branded competitors alike, GlaxoSmithKline is grooming a lineup of respiratory up-and-comers to step in with their own blockbuster sales. And new study results comparing Advair with not-yet-launched Anoro Ellipta could help the fledgling COPD treatment do just that.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: